Phospho-ATP1A1 (S16) Antibody

What is ATP1A1 and what is the significance of its phosphorylation at Serine 16?

ATP1A1 encodes the α1 subunit of the sodium-potassium ATPase, an electrogenic cation pump that is highly expressed in the nervous system . This enzyme catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane, creating the electrochemical gradient necessary for active transport of various nutrients . Phosphorylation at Serine 16 (S16) is mediated by phorbol ester-sensitive protein kinase C (PKC) and plays a crucial role in regulating the pump's activity . This post-translational modification appears to increase the apparent sodium affinity of Na,K-ATPase, thereby enhancing its transport activity under specific experimental conditions . The significance of this phosphorylation extends beyond simple regulation, as aberrant phosphorylation of ATP1A1 has been linked to various diseases, making it a valuable biomarker for pathological studies .

How can researchers detect phosphorylation of ATP1A1 at Serine 16?

Researchers can employ several complementary approaches to detect ATP1A1 phosphorylation at Serine 16:

• Antibody-based detection: Phospho-specific antibodies like the Anti-Phospho-ATP1A1-Ser16 antibody can detect endogenous levels of Na+/K+-ATPase Alpha 1 protein only when phosphorylated at S16 . These antibodies can be used in multiple applications:

  • Western blotting (recommended dilution 1:500-1:2000)

  • Immunohistochemistry (recommended dilution 1:100-1:300)

  • Immunofluorescence (recommended dilution 1:50-200)

  • ELISA (recommended dilution 1:5000)

• Cell-based ELISA kits: These provide a lysate-free, high-throughput approach for measuring relative amounts of phosphorylated ATP1A1 in cultured cells and screening effects of various treatments .

• Mutagenesis studies: Comparison of wild-type ATP1A1 with mutant forms (such as T15A/S16A or S16D-E) in expression systems to assess functional consequences of phosphorylation .

What experimental controls should be included when studying ATP1A1 phosphorylation?

When studying ATP1A1 phosphorylation, several critical controls should be implemented:

• Phosphorylation-null mutants: Cells expressing ATP1A1 with mutations at Ser-16 (e.g., S16A) should show no reactivity with phospho-specific antibodies and can serve as negative controls .

• Phosphomimetic mutants: S16D or S16E mutations that mimic constitutive phosphorylation can be used to confirm functional effects of phosphorylation . In studies using the ouabain-resistant Bufo α1 subunit, these mutants exhibited increased apparent Na affinity, confirming effects seen in phosphorylated wild-type proteins .

• Pharmacological controls:

  • PKC activators like phorbol 12,13-dibutyrate (PDBu) to induce phosphorylation

  • PKC inhibitors to confirm specificity of phosphorylation events

• Total ATP1A1 detection: Always measure total ATP1A1 protein levels alongside phosphorylated forms to normalize results and account for changes in protein expression .

How does temperature affect experimental outcomes when studying ATP1A1 phosphorylation?

Temperature has a profound impact on experimental outcomes when studying ATP1A1 phosphorylation and can help reveal distinct regulatory mechanisms:

These temperature-dependent differences may partially account for contradictory results reported in the literature regarding PKC regulation of Na,K-ATPase . Researchers should carefully consider temperature conditions when designing experiments to study specific aspects of ATP1A1 regulation. At 37°C, the physiological effects observed represent a combination of phosphorylation-dependent and phosphorylation-independent mechanisms, while lower temperatures can help isolate the direct effects of Ser-16 phosphorylation .

What signaling pathways regulate ATP1A1 phosphorylation at Serine 16?

ATP1A1 phosphorylation at Serine 16 is regulated through multiple interconnected signaling pathways:

• Protein Kinase C (PKC) pathway: Phorbol ester-sensitive PKC directly phosphorylates the α1 subunit at Ser-16 . This can be experimentally induced using phorbol 12,13-dibutyrate (PDBu) .

• Arachidonic acid pathway: Arachidonic acid can mimic the effects of PDBu on Na,K-ATPase, suggesting cross-talk between lipid signaling and PKC activation .

• Phospholipase A2 pathway: The PDBu effect on Na,K-ATPase is dependent on phospholipase A2 activity, indicating that phospholipid metabolism plays a role in regulating ATP1A1 phosphorylation .

• Cytochrome P450-dependent monooxygenase pathway: This pathway is also involved in the PKC-mediated regulation of Na,K-ATPase, suggesting a complex interplay between multiple enzymatic systems .

Understanding these regulatory pathways is essential for proper experimental design when studying ATP1A1 phosphorylation. Researchers should consider using specific inhibitors for each pathway to dissect their relative contributions to the observed phenotypes.

How do mutations in ATP1A1 affect its phosphorylation status and function?

Mutations in ATP1A1 can significantly impact both its phosphorylation status and function, with important implications for human disease:

• Effect on ATPase function: De novo ATP1A1 variants (c.674A>G;p.Gln225Arg, c.1003G>T;p.Gly335Cys, c.1526G>A;p.Gly509Asp, c.2152G>A;p.Gly718Ser, and c.2768T>A;p.Phe923Tyr) lead to significantly decreased cell viability in functional assays, indicating loss of ATPase function .

• Disease associations: Pathogenic variants in ATP1A1 are associated with complex phenotypes including:

  • Intellectual disability

  • Spasticity

  • Peripheral, motor predominant neuropathy

  • Sensory loss

  • Sleep disturbances

  • Seizures

• Mechanistic insights: Heterozygous missense mutations in ATP1A1 lead to reduced ATPase function, indicating haploinsufficiency as a disease mechanism . This suggests that proper phosphorylation regulation may be disrupted in pathological conditions.

• Structural implications: Mutations affecting conserved amino acid residues in constrained regions (as indicated by high GERP scores of 4.82–5.33) can disrupt normal protein function and potentially alter phosphorylation sites or the protein's response to phosphorylation .

When studying disease-associated variants, researchers should consider examining both their impact on baseline ATPase function and their effect on phosphorylation-dependent regulation.

How can researchers effectively distinguish between phosphorylation-dependent and phosphorylation-independent effects on Na,K-ATPase?

Distinguishing between phosphorylation-dependent and phosphorylation-independent effects on Na,K-ATPase requires sophisticated experimental approaches:

• Mutagenesis strategy: Compare wild-type ATP1A1 with:

  • Phosphorylation-null mutants (T15A/S16A) that cannot be phosphorylated

  • Phosphomimetic mutants (S16D-E) that mimic constitutive phosphorylation

• Temperature manipulation: Conduct experiments at both 37°C and 18°C, as lower temperatures suppress phosphorylation-independent down-regulation of Na,K-pumps and reveal phosphorylation-dependent stimulation of transport activity .

• Pharmacological dissection: Use specific inhibitors to target:

  • PKC (direct phosphorylation)

  • Phospholipase A2 (phosphorylation-independent mechanism)

  • Cytochrome P450-dependent monooxygenase (phosphorylation-independent mechanism)

• Functional readouts: Measure multiple parameters including:

  • Transport activity (direct functional consequence)

  • Cell surface expression (trafficking effect)

  • Apparent Na affinity (kinetic parameter affected by phosphorylation)

By implementing these approaches, researchers have revealed that PKC activation leads to both:

• A phosphorylation-independent decrease in cell surface expression of Na,K-pumps

• A phosphorylation-dependent stimulation of transport activity attributable to increased apparent Na affinity

This methodological approach can help resolve contradictory results reported in the literature regarding PKC regulation of Na,K-ATPase.

What methodologies are most effective for studying ATP1A1 phosphorylation in neurological disease models?

When investigating ATP1A1 phosphorylation in neurological disease models, researchers should consider these methodological approaches:

• Genetic models:

  • Use cells expressing ouabain-resistant ATP1A1 constructs (e.g., from Bufo) to distinguish exogenous pump activity from endogenous activity

  • Create disease-specific mutations identified in patients (such as c.674A>G;p.Gln225Arg or c.1003G>T;p.Gly335Cys) to study their effect on phosphorylation and function

• Functional assays:

  • Cell viability assays after ouabain treatment can assess ATPase function in cells expressing mutant constructs

  • Measure the viability ratio of treated and untreated cells to normalize results

• Phosphorylation-specific detection:

  • Use phospho-specific antibodies that detect endogenous levels of Na+/K+-ATPase Alpha 1 only when phosphorylated at S16

  • Employ cell-based ELISA kits for high-throughput screening of phosphorylation in response to various treatments

• In vivo validation:

  • Correlate clinical phenotypes (intellectual disability, spasticity, neuropathy) with molecular findings

  • Consider how phosphorylation status changes in different neurological contexts

• Statistical analysis:

  • Use appropriate statistical methods such as one-way ANOVA with Tukey post-test for α-error correction when comparing multiple groups

This integrated approach combining genetic, biochemical, and clinical data provides the most comprehensive insights into the role of ATP1A1 phosphorylation in neurological diseases.

How does ATP1A1 phosphorylation at Serine 16 influence its interaction with other cellular components?

ATP1A1 phosphorylation at Serine 16 affects multiple aspects of its interaction with cellular components:

• Effect on sodium affinity: Phosphorylation at Ser-16 increases the apparent Na affinity of Na,K-ATPase, as demonstrated in both:

  • Cells expressing phosphomimetic mutants (S16D or S16E)

  • PDBu-induced increases in Na sensitivity in permeabilized cells

• Membrane trafficking: Although phosphorylation-independent mechanisms primarily govern cell surface expression, phosphorylation may influence the protein's interactions with trafficking machinery .

• Signaling functions: Beyond its ion transport role, ATP1A1 participates in osmosensory signaling pathways that:

  • Sense body-fluid sodium levels

  • Control salt intake behavior

  • Regulate voluntary water intake to maintain sodium homeostasis
    Phosphorylation likely modulates these non-canonical functions.

• Energy utilization: By altering sodium affinity, phosphorylation potentially affects the efficiency of ATP utilization by the pump, which has broader implications for cellular energy homeostasis .

Understanding these complex interactions requires integrated approaches combining biochemical, cell biological, and physiological methods to fully elucidate the multilayered regulation of Na,K-ATPase function by phosphorylation.

What are the optimal conditions for Phospho-ATP1A1 (S16) antibody use in different experimental applications?

Optimizing experimental conditions for Phospho-ATP1A1 (S16) antibody applications requires attention to several technical parameters:

For all applications, researchers should consider:

• Storage at -20°C for up to 1 year from receipt date

• Avoiding repeat freeze-thaw cycles to maintain antibody integrity

• Including appropriate positive and negative controls

• Using fresh reagents with phosphatase inhibitors to prevent dephosphorylation during sample preparation

The antibody's specificity for detecting endogenous levels of Na+/K+-ATPase Alpha 1 protein only when phosphorylated at S16 makes it a valuable tool, but this specificity depends on maintaining optimal experimental conditions .

How can researchers effectively validate their findings on ATP1A1 phosphorylation in different experimental systems?

Comprehensive validation of ATP1A1 phosphorylation findings requires a multi-faceted approach:

• Multiple detection methods:

  • Complement antibody-based detection with functional assays

  • Use both colorimetric and fluorescence-based detection systems

  • Apply mass spectrometry for direct phosphorylation site verification

• Genetic validation:

  • Compare wild-type ATP1A1 with phosphorylation-site mutants (S16A, S16D, S16E)

  • Use CRISPR/Cas9 to create cell lines with endogenous ATP1A1 mutations

  • Employ RNA interference to assess effects of reduced ATP1A1 expression

• Pharmacological validation:

  • Use multiple PKC activators beyond PDBu (e.g., different phorbol esters)

  • Apply specific PKC inhibitors to confirm phosphorylation dependency

  • Test effects of phosphatase inhibitors to enhance phosphorylation signal

• Cross-species validation:

  • Confirm findings in multiple cell types and model organisms

  • Consider that the Bufo α1 subunit is mainly phosphorylated by PKC on Ser-16 with residual 10% phosphorylation on Thr-15

• Cell-based functional assays:

  • Measure ion transport activity under varied conditions

  • Assess cell viability with specific perturbations (e.g., ouabain treatment)

  • Quantify membrane localization through surface biotinylation or imaging

Through this systematic validation process, researchers can establish robust, reproducible findings regarding ATP1A1 phosphorylation and its functional consequences.

What are the emerging research directions for studying ATP1A1 phosphorylation in neurological disorders?

Research on ATP1A1 phosphorylation in neurological disorders is evolving in several promising directions:

• Expanded genotype-phenotype correlations: Further studies are needed to expand the genotype-phenotype spectrum of ATP1A1 variants, as only 16 families worldwide had been reported with pathogenic ATP1A1 variants as of 2022 . This limited dataset constrains our understanding of how specific mutations affect phosphorylation and function.

• Therapeutic targeting: Understanding how phosphorylation regulates Na,K-ATPase function opens possibilities for developing therapeutics that could modulate this process in neurological disorders characterized by ATP1A1 dysfunction.

• Interaction with other ATPase subunits: Given that pathogenic variants in other subunits of the same ATPase (encoded by ATP1A2 or ATP1A3) are associated with conditions like hemiplegic migraine, dystonia, or cerebellar ataxia , research into how phosphorylation affects the interaction between different subunits is critical.

• Integration with broader signaling networks: Beyond its role in ion transport, ATP1A1 participates in osmosensory signaling pathways that regulate sodium homeostasis . Understanding how phosphorylation modulates these non-canonical functions could reveal new aspects of neurological disease mechanisms.

• Development of phosphorylation-specific therapeutic approaches: As our understanding of the functional consequences of Ser-16 phosphorylation improves, targeted approaches to modulate this specific post-translational modification could emerge as potential therapeutic strategies.